The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab plus chemotherapy in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: A pooled analysis of the CRYSTAL and OPUS studies.
Claus-Henning Kohne
Honoraria - Amgen; Merck Serono; Pfizer; Roche
Research Funding - Amgen; GlaxoSmithKline; Merck Serono; Pfizer; Roche
Carsten Bokemeyer
Consultant or Advisory Role - Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Roche; Sanofi
Honoraria - Merck Serono; Roche; Sanofi
Research Funding - Merck Serono; Roche
Ute Sartorius
Employment or Leadership Position - Merck KGaA
Michael Schlichting
Employment or Leadership Position - Merck KGaA
Philippe Rougier
Consultant or Advisory Role - Merck Serono; Pfizer; Sanofi
Honoraria - Merck Serono; Roche; Sanofi
Research Funding - Roche
Eric Van Cutsem
Consultant or Advisory Role - Merck Serono
Research Funding - Merck Serono